{"description":"Documents matching 'marijuana', published on or after 04/29/2026, and from Drug Enforcement Administration","count":26,"total_pages":2,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bagencies%5D%5B%5D=drug-enforcement-administration&conditions%5Bpublication_date%5D%5Bgte%5D=2026-04-29&conditions%5Bterm%5D=marijuana&format=json&page=2","results":[{"title":"Decision and Order: Medpharm Research, LLC","type":"Notice","abstract":null,"document_number":"2026-20553","html_url":"https://www.federalregister.gov/documents/2026/10/07/2026-20553/decision-and-order-medpharm-research-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-07/pdf/2026-20553.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20553.pdf?1791290716","publication_date":"2026-10-07","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"(e), (f)(1). \n II. Applicable Law \n \n <span class=\"match\">Marijuana</span>, as defined in the CSA, as well as <span class=\"match\">marijuana</span> extract and tetrahydrocannabinols \n 3 \n \n (hereinafter collectively referred to as <span class=\"match\">marijuana</span>), are Schedule I controlled substances, unless they are in a U.S. Food and Drug Administration approved product or subject to a state medical <span class=\"match\">marijuana</span> license under 21 CFR 1308.13(g) as Schedule III controlled substances. 21 U.S.C. 812(c), Schedule I(c)(10); 21 CFR 1308.11(d)(23), (31), (58); RFAAX 1, at 1.\n \n \n \n 3 \n  <span class=\"match\">Marijuana</span> extract and tetrahydrocannabinols are"},{"title":"JT Medical, LLC; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-19842","html_url":"https://www.federalregister.gov/documents/2026/09/29/2026-19842/jt-medical-llc-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-29/pdf/2026-19842.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19842.pdf?1790599512","publication_date":"2026-09-29","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Approved Products Containing <span class=\"match\">Marijuana</span> From Schedule I to Schedule III; Corresponding Change to Permit Requirements, \n 91 FR 22714, 22721 (2026) (adding paragraph (k) to 21 CFR 1301.13 “establish[ing] an expedited review process for entities holding state medical <span class=\"match\">marijuana</span> licenses who seek registration as a <span class=\"match\">marijuana</span> manufacturer”); \n see also id. \n at 22722 (adding paragraphs (g)(2)-(4) to 21 CFR 1308.13 placing into schedule III marihuana, marihuana extract, and delta-9-tetrahydrocannabinols “subject to a state medical <span class=\"match\">marijuana</span> license”).\n \n \n Order"},{"title":"Muhamad Aly Rifai, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-21258","html_url":"https://www.federalregister.gov/documents/2026/10/19/2026-21258/muhamad-aly-rifai-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-19/pdf/2026-21258.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-21258.pdf?1792154712","publication_date":"2026-10-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"anxiety or lessen alcohol use, or that she possessed a medical <span class=\"match\">marijuana</span> card. RFAAX 28, at 6. The transcripts of UC's interaction with Respondent and his staff confirm UC's statement that she never told Respondent that she had used cannabis or possessed a <span class=\"match\">marijuana</span> card. \n See \n RFAAX 39, at 1-26; \n see also \n RFAAX 28, at 1-7. However, Respondent's records include an evaluation stating that “[UC] admits to periodic cannabis use to help anxiety, less alcohol use. Reports Medical <span class=\"match\">Marijuana</span> Card. Could not find her name in the Medical Cannabis Registry"},{"title":"Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places methyl 2-[[1-(4-fluorobutyl)indole-3- carbonyl]amino]-3,3-dimethyl-butanoate (other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA), N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1- yl)-1H-indazole-3-carboxamide (other name: ADB-4en-PINACA), ethyl 2- [[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (other names: 5F-EDMB-PICA; 5F-EDMB-2201), and methyl 2-(1-(4- fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate (other name: MMB-FUBICA), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4F-MDMB-BUTICA, ADB- 4en-PINACA, 5F-EDMB-PICA, or MMB-FUBICA.","document_number":"2026-08517","html_url":"https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08517.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08517.pdf?1777553120","publication_date":"2026-05-01","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"the placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA into schedule I of the CSA. \n \n Comment that was not related to this rulemaking: \n DEA received one comment that was neither explicitly for nor against the proposed rule. This comment discussed <span class=\"match\">marijuana</span> and was not related to the current scheduling action.\n \n \n DEA Response: \n This comment was outside the scope of the current scheduling action; therefore, it was not considered.\n \n Scheduling Conclusion \n After consideration of the public comment, scientific and medical"},{"title":"Schedules of Controlled Substances: Placement of Diphenidine in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places the substance diphenidine (1-(1,2- diphenylethyl)piperidine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle diphenidine.","document_number":"2026-19231","html_url":"https://www.federalregister.gov/documents/2026/09/21/2026-19231/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-09-21/pdf/2026-19231.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-19231.pdf?1789735510","publication_date":"2026-09-21","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently"},{"title":"Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3- b]indol-1-one (other names: CUMYL-PEGACLONE; SGT-151), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.","document_number":"2026-09566","html_url":"https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09566.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-09566.pdf?1778589924","publication_date":"2026-05-13","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently"},{"title":"Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I","type":"Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2- [(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.","document_number":"2026-12654","html_url":"https://www.federalregister.gov/documents/2026/06/24/2026-12654/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12654.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12654.pdf?1782218712","publication_date":"2026-06-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Alexandra R. Lovec, A.P.R.N.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-20751","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20751/alexandra-r-lovec-aprn-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20751.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20751.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":" M.D., \n 82 FR 14944, 14982 (2017). The Agency reviewed dictionary definitions of “experience,” including:\n \n \n \n 6 \n  Historically, the Agency referred to “Factor B” as “Factor Two.” Effective December 2, 2022, the Medical <span class=\"match\">Marijuana</span> and Cannabidiol Research Expansion Act, Public Law 117-215, 136 Stat. 2257 (2022) (<span class=\"match\">Marijuana</span> Research Amendments or MRA), amended the CSA and other statutes. Relevant to this matter, the MRA redesignated the public interest factors outlined at 21 U.S.C. 823(f)(1)-(5), which the Agency referred to as Factors One through"},{"title":"Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I","type":"Rule","abstract":"The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.","document_number":"2026-16413","html_url":"https://www.federalregister.gov/documents/2026/08/12/2026-16413/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16413.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16413.pdf?1786452314","publication_date":"2026-08-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I","type":"Rule","abstract":"The Drug Enforcement Administration (DEA) issues this temporary order to schedule 2-(2-fluorophenyl)-2- (methylamino)cyclohexan-1-one (commonly known as 2- fluorodeschloroketamine or 2-FDCK), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing 2-fluorodeschloroketamine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle this substance.","document_number":"2026-10253","html_url":"https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-22/pdf/2026-10253.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10253.pdf?1779367509","publication_date":"2026-05-22","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act","type":"Proposed Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-5,6-dichloro-1,3-dihydro- 2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4-chlorobenzyl)piperidin-4-yl)-1,3- dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3-(1-(1-(4- chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these four specific substances.","document_number":"2026-13364","html_url":"https://www.federalregister.gov/documents/2026/07/01/2026-13364/schedules-of-controlled-substances-temporary-placement-of-56--dichloro-brorphine-56-dichloro","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-01/pdf/2026-13364.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13364.pdf?1782823521","publication_date":"2026-07-01","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Katherine Curtis, N.P.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-20937","html_url":"https://www.federalregister.gov/documents/2026/10/14/2026-20937/katherine-curtis-np-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-14/pdf/2026-20937.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20937.pdf?1791895515","publication_date":"2026-10-14","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":" M.D., \n 82 FR 14944, 14982 (2017). The Agency reviewed dictionary definitions of “experience,” including:\n \n \n \n 9 \n  Historically, the Agency referred to “Factor B” as “Factor Two.” Effective December 2, 2022, the Medical <span class=\"match\">Marijuana</span> and Cannabidiol Research Expansion Act, Public Law 117-215, 136 Stat. 2257 (2022) (<span class=\"match\">Marijuana</span> Research Amendments or MRA), amended the CSA and other statutes. Relevant to this matter, the MRA redesignated the public interest factors outlined at 21 U.S.C. 823(f)(1)-(5), which the Agency referred to as Factors One through"},{"title":"Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration (DEA) is issuing this notice of intent to publish a temporary order to schedule two 7- hydroxymitragynine-related substances (MGM-15 and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act (CSA). On August 26, 2026, DEA published a temporary order placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I of the CSA. Today, DEA is providing notice of its intent to publish a new temporary order for MGM-15 and MGM-16 that will maintain the temporary placement of these substances in schedule I of the CSA without change. Separately in this Federal Register, DEA is publishing a notice of intent relating to mitragynine pseudoindoxyl, in response to a letter sent by the Department of Health and Human Services (HHS) dated October 6, 2026. HHS's letter related only to mitragynine pseudoindoxyl. Therefore, DEA is publishing this notice of intent only for the technical and procedural purpose of distinguishing MGM-15 and MGM-16 from mitragynine pseudoindoxyl. When issued, the temporary scheduling order addressing MGM-15 and MGM-16 will continue to impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these two 7-hydroxymitragynine-related substances. The August 26, 2026 temporary order placing these substances in schedule I of the CSA remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first.","document_number":"2026-20942","html_url":"https://www.federalregister.gov/documents/2026/10/14/2026-20942/schedules-of-controlled-substances-temporary-placement-of-mgm-15-and-mgm-16-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-14/pdf/2026-20942.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20942.pdf?1791561615","publication_date":"2026-10-14","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Vladimir Romaniv, P.A.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-20749","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20749/vladimir-romaniv-pa-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20749.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20749.pdf?1791463513","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Pope, MD, \n 82 FR 14944, 14982 (2017). The Agency reviewed dictionary definitions of “experience,” including:\n \n \n \n 14 \n  Historically, the Agency referred to “Factor B” as “Factor Two.” Effective December 2, 2022, the Medical <span class=\"match\">Marijuana</span> and Cannabidiol Research Expansion Act, Public Law 117-215, 136 Stat. 2257 (2022) (<span class=\"match\">Marijuana</span> Research Amendments or MRA), amended the CSA and other statutes. Relevant to this matter, the MRA redesignated the public interest factors outlined at 21 U.S.C. 823(f)(1)-(5), which the Agency referred to as Factors One through"},{"title":"Schedules of Controlled Substances: Placement of Diphenidine in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing diphenidine (1-(1,2-diphenylethyl)piperidine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle diphenidine.","document_number":"2026-10380","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10380.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10380.pdf?1779453913","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; \n \n Remand,\n \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently"},{"title":"Arenbii Pharmacy LLC; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-20535","html_url":"https://www.federalregister.gov/documents/2026/10/07/2026-20535/arenbii-pharmacy-llc-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-07/pdf/2026-20535.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20535.pdf?1791290714","publication_date":"2026-10-07","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":" M.D., \n 82 FR 14944, 14982 (2017). The Agency reviewed dictionary definitions of “experience,” including:\n \n \n \n 6 \n  Historically, the Agency referred to “Factor B” as “Factor Two.” Effective December 2, 2022, the Medical <span class=\"match\">Marijuana</span> and Cannabidiol Research Expansion Act, Public Law 117-215, 136 Stat. 2257 (2022) (<span class=\"match\">Marijuana</span> Research Amendments or MRA), amended the CSA and other statutes. Relevant to this matter, the MRA redesignated the public interest factors outlined at 21 U.S.C. 823(f)(1-5), which the Agency referred to as Factors One through"},{"title":"Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act","type":"Rule","abstract":"The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.","document_number":"2026-17531","html_url":"https://www.federalregister.gov/documents/2026/08/27/2026-17531/schedules-of-controlled-substances-temporary-placement-of-56-dichloro-brorphine-56-dichloro","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-27/pdf/2026-17531.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-17531.pdf?1787748320","publication_date":"2026-08-27","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I","type":"Proposed Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule 7-hydroxymitragynine above a specified threshold, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 7-hydroxymitragynine above a specified threshold.","document_number":"2026-13580","html_url":"https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-06/pdf/2026-13580.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13580.pdf?1782936911","publication_date":"2026-07-06","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"},{"title":"Schedules of Controlled Substances: Placement of Tianeptine in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing the substance tianeptine (7-[(3-chloro-6,11-dihydro-6-methyl-5,5- dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, salts, and salts of isomers, esters, and ethers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle tianeptine.","document_number":"2026-13821","html_url":"https://www.federalregister.gov/documents/2026/07/08/2026-13821/schedules-of-controlled-substances-placement-of-tianeptine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-08/pdf/2026-13821.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13821.pdf?1783428319","publication_date":"2026-07-08","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug \n \n must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n See <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently"},{"title":"Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I","type":"Proposed Rule","abstract":"The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.","document_number":"2026-13581","html_url":"https://www.federalregister.gov/documents/2026/07/06/2026-13581/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-06/pdf/2026-13581.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13581.pdf?1782936911","publication_date":"2026-07-06","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"chemistry must be known and reproducible; (2) there must be adequate safety studies; (3) there must be adequate and well-controlled studies proving efficacy; (4) the drug must be accepted by qualified experts; and (5) the scientific evidence must be widely available. \n <span class=\"match\">Marijuana</span> Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA applied the traditional five-part test and concluded the"}]}